Isoprinosine reduced clinical progression in HIV infected patients in a double blind placebo controlled study. NLM AIDSLINE Important note: Information in this article was accurate in 1990. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Isoprinosine reduced clinical progression in HIV infected patients in a double blind placebo controlled study.

Int Conf AIDS. 1989 Jun 4-9;5:219 (abstract no. Th.B.O.46). Unique Identifier : AIDSLINE ICA5/00095189
Hidovre, Denmark

Abstract: OBJECTIVE: To determine the influence of isoprinosine (Imunovir) on the clinical course of HIV infection. METHODS: A total of 866 HIV infected patients from Sweden and Denmark were randomised and stratified according to CD4-count to receive either isoprinosine 1 g t.i.d. (n=429) or matching placebo (n=437) for 6 months. At baseline the study population consisted of 765 asymptomatic patients and 101 symptomatic patients. Patients with AIDS were not included. RESULTS: Eight hundred and thirty-three patients were eligible for efficacy analysis. There were no significant differences between the two groups with respect to CD4-count or clinical status at baseline. Progression to AIDS according to CDC revised definition: TABULAR DATA, SEE ABSTRACT VOLUME. During treatment no significant differences in CD4-count occurred. No serious side effects were observed. Minor adverse reactions occurred with equal frequencies in both groups. CONCLUSION: Isoprinosine offers a potential treatment modality, particularly in the asymptomatic HIV infected patients. However, the mode of action remains to be clarified.
Keywords: *Clinical Trials CD4-Positive T-Lymphocytes Denmark Double-Blind Method Human HIV Infections/*DRUG THERAPY/PHYSIOPATHOLOGY Inosine Pranobex/*THERAPEUTIC USE Placebos Sweden ABSTRACTKWDclinicaltrialscd4-positivet-lymphocytesdenmarkdouble-blindmethodhumanhivinfections/KWDdrugtherapy/physiopathologyinosinepranobex/KWDtherapeuticuseplacebosswedenabstract
900930
M9094724

Copyright © 1990 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1990. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1990. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .